[{"address1": "200 Granville Street", "address2": "Suite 2820", "city": "Vancouver", "state": "BC", "zip": "V6C 1S4", "country": "Canada", "phone": "604 336 7906", "website": "https://www.aequuspharma.ca", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial. The company has a strategic collaboration with reVision for the development of a therapy for stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Douglas Glen Janzen", "age": 54, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 0.0044, "dayLow": 0.0044, "dayHigh": 0.0044, "regularMarketOpen": 0.0044, "regularMarketDayLow": 0.0044, "regularMarketDayHigh": 0.0044, "volume": 209000, "regularMarketVolume": 209000, "averageVolume": 10000, "averageVolume10days": 28902, "averageDailyVolume10Day": 28902, "bid": 0.0044, "ask": 0.0089, "marketCap": 676433, "fiftyTwoWeekLow": 0.0044, "fiftyTwoWeekHigh": 0.0266, "priceToSalesTrailing12Months": 1.6371982, "fiftyDayAverage": 0.0080144, "twoHundredDayAverage": 0.01297595, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 7145704, "floatShares": 112794973, "sharesOutstanding": 132634000, "heldPercentInsiders": 0.1468, "impliedSharesOutstanding": 143259008, "bookValue": -0.047, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -2675722, "trailingEps": -0.01, "enterpriseToRevenue": 17.295, "enterpriseToEbitda": -2.787, "52WeekChange": -0.7811159, "SandP52WeekChange": 0.31754446, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "AQSZF", "underlyingSymbol": "AQSZF", "shortName": "Aequus Pharmaceuticals Inc.", "longName": "Aequus Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1434461400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "69ca53f2-e460-3763-b252-eb51c2814c3d", "messageBoardId": "finmb_247433914", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.0051, "recommendationKey": "none", "totalCash": 70258, "totalCashPerShare": 0.001, "ebitda": -2564213, "totalDebt": 6539527, "quickRatio": 0.021, "currentRatio": 0.047, "totalRevenue": 413165, "revenuePerShare": 0.003, "returnOnAssets": -1.5823101, "freeCashflow": -1505963, "operatingCashflow": -2478615, "revenueGrowth": 10.103, "grossMargins": 0.53448004, "operatingMargins": -4.15289, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-12-07"}]